BlackRock’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $185M | Buy |
3,861,182
+909,829
| +31% | +$39.1M | ﹤0.01% | 1841 |
|
|
2026
Q1 | $108M | Sell |
2,951,353
-283,549
| -9% | -$13.4M | ﹤0.01% | 2056 |
|
|
2025
Q4 | $165M | Sell |
3,234,902
-728,787
| -18% | -$37.3M | ﹤0.01% | 1807 |
|
|
2025
Q3 | $220M | Sell |
3,963,689
-394,520
| -9% | -$23.1M | ﹤0.01% | 1613 |
|
|
2025
Q2 | $301M | Buy |
4,358,209
+79,010
| +2% | +$5.37M | 0.01% | 1364 |
|
|
2025
Q1 | $297M | Sell |
4,279,199
-614,407
| -13% | -$50.7M | 0.01% | 1349 |
|
|
2024
Q4 | $421M | Sell |
4,893,606
-620,558
| -11% | -$67.1M | 0.01% | 1194 |
|
|
2024
Q3 | $657M | Buy |
5,514,164
+52,019
| +1% | +$6.94M | 0.01% | 882 |
|
|
2024
Q2 | $780M | Sell |
5,462,145
-102,926
| -2% | -$13.6M | 0.02% | 714 |
|
|
2024
Q1 | $715M | Sell |
5,565,071
-1,732,848
| -24% | -$206M | 0.02% | 796 |
|
|
2023
Q4 | $755M | Sell |
7,297,919
-754,387
| -9% | -$74.6M | 0.02% | 717 |
|
|
2023
Q3 | $732M | Sell |
8,052,306
-364,332
| -4% | -$32.1M | 0.02% | 676 |
|
|
2023
Q2 | $681M | Sell |
8,416,638
-194,896
| -2% | -$15.9M | 0.02% | 731 |
|
|
2023
Q1 | $685M | Sell |
8,611,534
-636,796
| -7% | -$45.2M | 0.02% | 711 |
|
|
2022
Q4 | $626M | Sell |
9,248,330
-162,202
| -2% | -$9.51M | 0.02% | 749 |
|
|
2022
Q3 | $469M | Buy |
9,410,532
+2,410,360
| +34% | +$129M | 0.02% | 857 |
|
|
2022
Q2 | $390M | Sell |
7,000,172
-3,071,586
| -30% | -$170M | 0.01% | 1041 |
|
|
2022
Q1 | $559M | Buy |
10,071,758
+3,143,494
| +45% | +$161M | 0.02% | 885 |
|
|
2021
Q4 | $388M | Buy |
6,928,264
+91,684
| +1% | +$4.97M | 0.01% | 1241 |
|
|
2021
Q3 | $328M | Buy |
6,836,580
+501,756
| +8% | +$24.3M | 0.01% | 1330 |
|
|
2021
Q2 | $265M | Sell |
6,334,824
-277,428
| -4% | -$10.8M | 0.01% | 1564 |
|
|
2021
Q1 | $223M | Buy |
6,612,252
+3,706,294
| +128% | +$132M | 0.01% | 1653 |
|
|
2020
Q4 | $101M | Sell |
2,905,958
-246,420
| -8% | -$8.52M | ﹤0.01% | 2072 |
|
|
2020
Q3 | $109M | Sell |
3,152,378
-124,656
| -4% | -$4.16M | ﹤0.01% | 1820 |
|
|
2020
Q2 | $107M | Sell |
3,277,034
-1,424,936
| -30% | -$45.5M | ﹤0.01% | 1798 |
|
|
2020
Q1 | $142M | Sell |
4,701,970
-784,910
| -14% | -$23.4M | 0.01% | 1410 |
|
|
2019
Q4 | $159M | Sell |
5,486,880
-6,944,138
| -56% | -$192M | 0.01% | 1666 |
|
|
2019
Q3 | $321M | Sell |
12,431,018
-3,285,934
| -21% | -$83.1M | 0.01% | 1072 |
|
|
2019
Q2 | $401M | Sell |
15,716,952
-1,169,862
| -7% | -$28.9M | 0.02% | 896 |
|
|
2019
Q1 | $442M | Buy |
16,886,814
+14,318
| +0.1% | +$352K | 0.02% | 808 |
|
|
2018
Q4 | $389M | Sell |
16,872,496
-1,122,226
| -6% | -$24.9M | 0.02% | 799 |
|
|
2018
Q3 | $424M | Sell |
17,994,722
-198,110
| -1% | -$4.83M | 0.02% | 865 |
|
|
2018
Q2 | $420M | Sell |
18,192,832
-1,198,736
| -6% | -$28.5M | 0.02% | 852 |
|
|
2018
Q1 | $478M | Buy |
19,391,568
+545,000
| +3% | +$14.3M | 0.02% | 731 |
|
|
2017
Q4 | $506M | Buy |
18,846,568
+14,584,800
| +342% | +$371M | 0.02% | 682 |
|
|
2017
Q3 | $103M | Buy |
4,261,768
+2,695,570
| +172% | +$60.9M | 0.01% | 1844 |
|
|
2017
Q2 | $33.6M | Buy |
1,566,198
+504,400
| +48% | +$10.2M | ﹤0.01% | 2480 |
|
|
2017
Q1 | $18.2M | Buy |
1,061,798
+1,056,798
| +21,136% | +$18.4M | ﹤0.01% | 2809 |
|
|
2016
Q4 | $90K | Buy |
5,000
+3,600
| +257% | +$65.3K | ﹤0.01% | 2613 |
|
|
2016
Q3 | $29K | Buy |
1,400
+1,000
| +250% | +$24.8K | ﹤0.01% | 3182 |
|
|
2016
Q2 | $11K | Buy |
+400
| New | +$11K | ﹤0.01% | 3396 |
|
Other funds holding NVO
F
BlackRock's NVO Position: Q2 2026 in Review
BlackRock increased its Novo Nordisk (NVO) stake by 31% in Q2 2026, buying an estimated $39.1M and bringing the position to 3,861,182 shares worth $185M. The position accounts for ﹤0.01% of the portfolio, ranked #1841.
BlackRock first reported a position in NVO in Q2 2016 and has held it in 41 quarters since. The position peaked at $780M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- BlackRock held 3,861,182 shares of Novo Nordisk worth $185M as of Q2 2026.
- BlackRock bought 909,829 Novo Nordisk shares in Q2 2026, an estimated $39.1M.
- Novo Nordisk made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1841 holding.
- BlackRock first reported a position in Novo Nordisk in Q2 2016 and has held it in 41 quarters since.
- BlackRock's Novo Nordisk position peaked at $780M in Q2 2024.
- 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.